CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix (Nasdaq: CRMD) will report its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before the market opens on Thursday, March 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CorMedix (Nasdaq: CRMD) will report its fourth quarter and full year 2025 financial results for the period ended December 31, 2025, before the market opens on Thursday, March 5, 2026. The company will host a corporate update conference call at 8:30am Eastern Time.
Investors can join by domestic phone 1-844-676-2922, international phone 1-412-634-6840, or via webcast.
Details
News Market Reaction – CRMD
On Mar 2, the day this news came out, CRMD closed 1.12% above the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Earnings release date
- March 5, 2026
- Q4 and full-year 2025 results to be reported before market open
- Conference call time
- 8:30am ET
- Corporate update conference call on March 5, 2026
- Domestic dial-in
- 1-844-676-2922
- US access number for earnings conference call
- International dial-in
- 1-412-634-6840
- International access number for earnings conference call
Historical Context
-
Planned participation in three March 2026 healthcare investor conferences.
-
Board authorized up to $75 million in stock repurchases through 2027.
-
Planned in-person and virtual Analyst Day with portfolio and pipeline updates.
-
Corporate overview scheduled at the 44th Annual J.P. Morgan Healthcare Conference.
-
CEO contract extension and board role changes alongside comments on cashflow strength.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
| Thursday, March 5th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.